Pancreatic Cancer, Thromboembolism
Conditions
Keywords
Thromboprophylaxis, Advanced Pancreatic Cancer
Brief summary
This is a prospective, randomized, multicenter, open-label, blinded-endpoint Phase III clinical trial to investigate the impact of thromboprophylaxis using innohep, beyond anticoagulation in the improvement of the clinical outcomes in active pancreatic cancer patients receiving systemic anti-neoplasmatic treatment. The number of patients that will be enrolled is 450. The enrollment period is 24 months and the follow up period is 10 months.
Detailed description
Pancreatic cancer (PC) has the worst prognosis of any malignancy. Venous thromboembolism (VTE) occurs in 1:5 PC patients and is associated with significantly reduced progression-free survival (PFS). Phase III randomised controlled trials concluded that targeted thromboprophylaxis with low molecular weight heparins (LMWH) resulted in an 82% reduction in the relative risk of VTE without increasing major bleeding events, and that 11 patients were needed to be treated to prevent one VTE during chemotherapy. The benefits observed in the many of reported studies could not be accounted for by VTE prevention alone. Numerous experimental studies have demonstrated the antitumour, anti-metastatic and chemo-resistance reversal effect of LMWH. The vast majority of the so far published evidence assessing the efficacy and safety of VTE prevention in ambulatory cancer patients is based on mixed patient populations with various types of cancers. Thus, current studies do not allow to estimate the real effect of long-term prophylaxis on clinical outcomes in selected homogeneous high-thrombotic risk patients. An approach more specific to PC and restricted to advanced or metastatic patients is a modern and attractive strategy to assess the benefit of thromboprophylaxis in VTE prevention and beyond anticoagulation. The objective of the imPaCT-PRO trial is to investigate the impact of thromboprophylaxis beyond anticoagulation in the improvement of the clinical outcomes in active PC patients receiving systemic anti-neoplasmatic treatment.
Interventions
DRUGInnohep
Patients will receive Tinzaparin sodium 20.000 Anti-Xa IU/ml in prefilled syringes. Administered at 175 Anti-Xa IU/Kgr of body weight, subcutaneously, once daily
DRUGChemotherapy: Gemcitabine + Nab-Paclitaxel
All patients will receive chemotherapy per clinical practice
Sponsors
Michalis Karamouzis
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
Prospective, randomized, multicenter, open-label, blinded-endpoint Phase III clinical trial
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Advanced or metastatic PC (confirmed by the recommended histological and imaging methods). 2. Age ≥ 18 years. 3. Planning to start 1st line chemotherapy with NabG. 4. Eastern Cooperative Group (ECOG) 0-2. 5. Life expectancy \>6 months. 6. Written informed consent.
Exclusion criteria
1. Subjects with contraindication to receive anticoagulant: 1. Any hypersensitivity to anticoagulant or excipients. 2. History of heparin-induced thrombocytopenia type II (HIT II). 3. Active major bleeding or pre-diathesis for major bleeding 4. Septic endocarditis. 2. Creatinine clearance \<20 mL/min according to Cockcroft-Gault formula. 3. Platelet count \< 50 G/L at inclusion. 4. Hepatic dysfunction defined as at least one of the following: AST and/or ALT \> 5 x ULN, bilirubin \> 2 x ULN. 5. Recent (\< 1 month) oncological surgery, major abdominal or thoracic surgery, major orthopedic surgery, vascular surgery. 6. Recent (\< 1 month) acute coronary syndrome or any other arterial thrombosis, thrombotic or hemorrhagic stroke. 7. Patients on chronic anticoagulation or on dual anti-platelet treatment. 8. Pregnancy/lactation or insufficient contraception during the study and up to 3 months after the study. 9. Severe concomitant disease that as per investigator's judgement is not compatible with participation in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS of patients | 12 months | PFS of patients receiving thromboprophylaxis with tinzaparin, in comparison with the PFS of patients not receiving such prevention |
| The number of VTE events during the trial | 12 months | All objectively confirmed VTE events during the study per treatment arm including symptomatic distal deep vein thrombosis (DVT), symptomatic or incidental proximal DVT (including iliac and cava thrombosis), symptomatic or incidental pulmonary embolism (PE) or both DVT and PE (co-primary endpoint) or fatal PE or vein thrombosis of rare localisation (i.e., splanchnic vein or cerebral vein thrombosis). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| VTE events | Through study completion, an average of 2 years | Incidence of VTE events, per event type, during the study per treatment arm |
| % of patients experiencing at least one major bleeding event | Through study completion, an average of 2 years | % of patients experiencing at least one major bleeding event, according to the International Society on Thrombosis and Haemostasis (ISTH) criteria during the study per treatment arm. |
| Change from baseline in QoL | at 4 and 10 months | Change from baseline in QoL at 4 months and 10 months per treatment arm. QoL will be determined with the EORTC QLQ-C30 version 3.0. and EORTC QOL-PAN26 questionnaires according to the corresponding scoring manual |
| Patients with complete or partial response | Through study completion, an average of 2 years | ORR, defined as the percentage of patients with complete response (CR) or partial response (PR) based on RECIST criteria |
| % of patients experiencing any bleeding event | Through study completion, an average of 2 years | % of patients experiencing any bleeding event, including major, clinically relevant non-major bleeding (CRNMB) and minor bleeding events during the study per treatment arm. |
Countries
Greece
Outcome results
None listed